Structure-activity relationship study to understand the estrogen receptor-dependent gene activation of aryl- and alkyl-substituted 1H-imidazoles

Journal of Medicinal Chemistry

Volumn 50, Issue 7, 2007, Pages 1475-1484

  Wiglenda, Thomas ^a   Gust, Ronald ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIS(4 HYDROXYPHENYL) 1H IMIDAZOLE; 5 ETHYL 1,2,4 TRIS(4 HYDROXYPHENYL) 1H IMIDAZOLE; CHLORINE; ESTROGEN RECEPTOR ALPHA; HYDROXYL GROUP; IMIDAZOLE DERIVATIVE; PHENYL GROUP; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL STRAIN MCF 7; CULTURE MEDIUM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; PHENOLS; RADIOLIGAND ASSAY; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS); UTERUS;

EID: 34147098054     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061106t     Document Type: Article

References (29)

1. Cosman, F.; Lindsay, R. Selective estrogen receptor modulators: Clinical spectrum. Endocr. Rev. 1999, 20, 418-434.
2. Nuttali, M. E.; Stroup, G. B.; Fisher, P. W.; Nadeau, D. P.; Gowen, M.; Suva. L. J. Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells. Am. J. Physiol. Cell Physiol. 2000, 279, C1550-C1557.
3. Barrett-Conner, E.; Cox D. A.; Anderson, P. W. The potential of SERMs for reducing the risk of coronary heart disease. Trends Endocrin. Met. 1999, 10, 320-325.
4. Stauffer, S. R.; Coletta C. J.; Tedesco R.; Nishiguchi G.; Carlson K.; Sun J.; Katzenellenbogen, B. S.; Katzenellenbogen J. A. Pryrazole ligands: Structure-affinity/activity relationship and estrogen receptor-α-selective agonists. J. Med. Chem. 2000, 43, 4934-4947.
5. Mortensen, D. S.; Rodriguez, A. L.; Carlson, K. E.; Sun, J.; Katzenellenbogen, B. S.; Katzenellenbogen J. A. Synthesis and biological evaluation of a novel series of furans: Ligands selective for estrogen receptor α. J. Med. Chem. 2001, 44, 3838-3848.
6. Gust, R.; Keilitz, R.; Schmidt, K. Investigations of new lead structures for the design of selective estrogen receptor modulators. J. Med. Chem. 2001, 44, 1963-1970.
7. Mull, E. S.; Sattigeri, V. J.; Rodriguez, A. L.; Katzenellenbogen, J. A. Aryl cyclopentadienyl tricarbonyl rhenium complexes: Novel ligands for the estrogen receptor with potential use as estrogen radiopharmaceuticals. Bioorg. Med. Chem. 2002, 10, 1381-1398.
8. von Rauch, M.; Schlenk, M.; Gust, R. Effect of C2-akylation, N-alkylation and N,N′-dialkylation on the stability and estrogen receptor interaction of (R,S)/(S,R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines. J. Med. Chem. 2004, 47, 915-927.
9. Gust, R.; Keilitz R.; Schmidt, K.; Synthesis, structural evaluation, and estrogen receptor interaction of 2,3-diarylpiperazines. J. Med. Chem. 2002, 45, 2325-2337.
10. Fink, B. E.; Mortensen, D. S.; Stauffer S, R.; Aron Z. D.; Katzenellenbogen J. A. Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens. Chem. Biol. 1999, 6, 205-219.
11. Gust, R.; Keilitz, R.; Schmidt, K.; von Rauch M. Synthesis, structural evaluation and estrogen receptor interaction of 4,5-bis(4-hydroxyphenyl) imidazoles. Arch. Pharm. Pharm. Med. Chem. 2002, 335, 463-471.
12. Gust, R.; Busch, S.; Keilitz, R.; Schmidt, K.; von Rauch, M. Investigation on the influence of halide substituents on the estrogen receptor interaction of 2,4,5-tris(4-hydroxyphenyl)imidazoles. Arch. Pharm. Pharm. Med. Chem. 2003, 336, 456-465.
13. Wiglenda, T.; Ott, I.; Kircher, B.; Schumacher, P.; Schuster, D.; Langer, T.; Gust, R. Synthesis and pharmacological evaluation of 1H-imidazoles as ligands of the estrogen receptor and cytotoxic inhibitors of the cyclooxygenase. J. Med. Chem. 2005, 48, 6516-6521.
14. Gautier, J.-A.; Miocque, M.; Fauran, C.; Le Cloareg, A.-Y. Préparation d'amidines à partir de nitriles et d'amines aromatiques en solvant ammoniac liquide. Bull. Soc. Chim. Fr. 1970, 1, 200-207.
15. Daoust, B.; Lessard, J. Eletrochemical behavior of amidine hydrochlorides and amidines. Can. J. Chem. 1995, 73, 362-374.
16. Wen, J.; Chen, H.; Zhang, Z. Synthesis of 4-methoxy(polyfluoro) benzonitriles. Patent CN 1190093, 1998.
17. Hafner, F.; Holler, E.; von Angerer, E. Effect of growth factors on estrogen receptor mediated gene expression. J. Steroid Biochem. Mol. Biol. 1996, 58, 385-393.
18. Biberger, C.; von Angerer, E. 1-Benzyl-2-phenylindole- and 1,2-diphenylindole-based antiestrogens. Estimation of agonist and antagonist activities in transfection assays. J. Steroid. Biochem. Mol. Biol. 1998, 64, 277-285.
19. Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. W.; Bonn, T.; Engström, O.; Öhman, L.; Greene, G. L.; Gustafsson, J.-Å.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389, 753-758.
20. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95, 927-937.
21. Kekenes-Huskey, P. K.; Muegge, I.; Gust, R.; Knapp, W. E. A molecular docking study of estrogenically active compounds with 1,2-diarylethane and 1,2-diarylethene pharmacophores. Bioorg. Med. Chem. 2004, 12, 6527-6537.
22. Jordan, V. C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. Clinical considerations and new agents. J. Med. Chem. 2005, 48, 6516-6521.
23. Jordan, V. C.; MacGregor Schafer, J. I.; Levenson, A. S.; Liu, H.; Pease, K. M.; Simons, L. A.; Zapf, J. W. Molecular classification of estrogens. Cancer Res. 2001, 61, 6619-6623.
24. McCague, R.; Kuroda, R.; Leclercq, G.; Stoessel, S. Synthesis and estrogen receptor binding of 6,7-dihydro-8-phenyl-9-[4-[2-(dimethylamino)ethoxy] phenyl]-5H-benzocycloheptene, a nonisomerizable analogue of tamoxifen. X-ray crystallographic studies. J. Med. Chem. 1986, 29, 2053-2059.
25. Gust, R.; Keilitz, R.; Schmidt, K.; von Rauch, M. (R,S)/( S,R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolines: Ligands for the estrogen receptor with a novel binding mode. J. Med. Chem. 2002, 45, 3356-3365.
26. Stauffer, S. R.; Huang, Y.; Coletta, C. J.; Tedesco, R.; Katzenellenbogen J. A. Estrogen pryrazoles: Defining the pyrazole core structure and the orientation of substituents in the ligand binding pocket of the estrogen receptor. Bioorg. Med. Chem. 2001, 9, 141-150.
27. Danielian, P. S.; White, R.; Hoare, S. A.; Fawell, S. E.; Parker, M. G. Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol. Endocrinol. 1993, 7, 232-240.
28. Gust, R.; Burgemeister, T.; Mannschreck, A.; Schönenberger, H. Aqua[1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] -sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 1. Synthesis and antitumor and estrogenic properties. J. Med. Chem. 1990, 33, 2535-2544.
29. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.